Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.54 |
| ▸ | ELANE | P08246 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PDE5A | O76074 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | GMNN | O75496 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20534349 | 0.89 | CNR1 (0.43) | CNR1ACHECNR2ELANEALDH1A1 | |
| SCHEMBL19328149 | 0.89 | CNR1 (0.43) | CNR1ACHECNR2ELANEALDH1A1 | |
| SCHEMBL14853614 | 0.88 | PTGER4 (0.47) | CNR1ACHECNR2ELANEALDH1A1 | |
| SCHEMBL20534347 | 0.86 | APP (0.48) | CNR1ACHECNR2ELANEALDH1A1 | |
| SCHEMBL14853618 | 0.86 | BUB1 (0.42) | CNR1ACHECNR2ELANEALDH1A1 | |
| SCHEMBL28253344 | 0.85 | ELANE (0.43) | CNR1ACHECNR2ELANEALDH1A1 | |
| SCHEMBL14842958 | 0.84 | CNR2 (0.62) | CNR1ACHECNR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL31512385 | 0.84 | CNR2 (0.62) | CNR1ACHECNR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL17876771 | 0.84 | TSHR (0.43) | CNR1ACHECNR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL20140445 | 0.83 | ELANE (0.41) | CNR1ACHECNR2ELANEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10675268-B2 | Somatostatin receptor subtype 4 (SSTR4) agonists | CENTREXION THERAPEUTICS CORPORATION (US) | 2020-06-09 | — | — | US | disclosed |
| US-10604532-B2 | Substituted benzylindazoles for use as BUB1 kinase inhibitors in the treatment of hyperproliferative diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2020-03-31 | — | — | US | disclosed |
| US-20190284206-A1 | SUBSTITUTED BENZYLINDAZOLES FOR USE AS BUB1 KINASE INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2019-09-19 | — | — | US | disclosed |
| US-20190269650-A1 | NEW SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2019-09-05 | — | — | US | disclosed |
| US-10266548-B2 | Substituted benzylindazoles for use as Bub1 kinase inhibitors in the treatment of hyperproliferative diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2019-04-23 | — | — | US | disclosed |
| US-10166214-B2 | Somatostatin receptor subtype 4 (SSTR4) agonists | CENTREXION THERAPEUTICS CORPORATION (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180092880-A1 | SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2018-04-05 | — | — | US | disclosed |
| US-20180092880-A1 | SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2018-04-05 | — | — | US | disclosed |
| EP-2763982-B1 | SUBSTITUTED BENZYLINDAZOLES FOR USE AS BUB1 KINASE INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES. | Bayer Pharma AG (DE) | 2018-01-10 | — | — | EP | disclosed |
| EP-2997021-B1 | NEW SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | CENTREXION THERAPEUTICS CORP (US) | 2017-12-20 | — | — | EP | disclosed |
| EP-0934311-B1 | NEW HETEROCYCLYLMETHYL-SUBSTITUTED PYRAZOL DERIVATES | BAYER HEALTHCARE AG (DE) | 2009-05-13 | — | — | EP | disclosed |
| WO-2007065010-A2 | ANTI-ANGIOGENESIS COMPOUNDS | HIF BIO, INC. (US) | 2007-06-07 | — | — | WO | disclosed |
| US-6462068-B1 | CARDIOVASCULAR DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2002-10-08 | — | — | US | disclosed |
| US-6414009-B1 | CARDIOVASCULAR DISORDERS; ANTICOAGULANTS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-07-02 | — | — | US | disclosed |
| US-6410740-B1 | CYCLIZATION OF THE CORRESPONDING AMIDE | BAYER AKTIENGESELLSCHAFT (DE) | 2002-06-25 | — | — | US | disclosed |
| US-6387940-B1 | CARDIOVASCULAR DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-05-14 | — | — | US | disclosed |
| US-6166027-A | Heterocyclylmethyl-substituted pyrazole derivatives and their use for treating cardiovascular diseases | BAYER AKTIENGESELLSCHAFT (DE) | 2000-12-26 | — | — | US | disclosed |
| CN-1241188-A | Heterocyclylmethyl-substed pyrazol derivs. | BAYER AG (DE) | 2000-01-12 | — | — | CN | disclosed |
| EP-0934311-A2 | NEW HETEROCYCLYLMETHYL-SUBSTITUTED PYRAZOL DERIVATES | BAYER AG (DE) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998016507-A2 | NEW HETEROCYCLYLMETHYL-SUBSTITUTED PYRAZOL DERIVATES AND THEIR USE FOR TREATING CARDIOVASCULAR DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 1998-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180092880-A1 | SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | SSTR4, SSTR3, SSTR1 | CNR1 129/4885ACHE 3014/4885CNR2 178/4885 |
| US-20190269650-A1 | NEW SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | SSTR4, SSTR3, SSTR1 | CNR1 97/4885ACHE 3400/4885CNR2 143/4885 |
| US-10604532-B2 | Substituted benzylindazoles for use as BUB1 kinase inhibitors in the treatment of hyperproliferative diseases | BUB1, BUB1B, BUB3 | CNR1 3404/4885ACHE 4858/4885CNR2 4075/4885 |
| US-20190284206-A1 | SUBSTITUTED BENZYLINDAZOLES FOR USE AS BUB1 KINASE INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BUB1, BUB1B, BUB3 | CNR1 3404/4885ACHE 4858/4885CNR2 4075/4885 |
| US-10675268-B2 | Somatostatin receptor subtype 4 (SSTR4) agonists | SSTR4, SSTR3, SSTR1 | CNR1 129/4885ACHE 3014/4885CNR2 178/4885 |
| US-10166214-B2 | Somatostatin receptor subtype 4 (SSTR4) agonists | SSTR4, SSTR3, SSTR1 | CNR1 129/4885ACHE 3014/4885CNR2 178/4885 |
| US-10266548-B2 | Substituted benzylindazoles for use as Bub1 kinase inhibitors in the treatment of hyperproliferative diseases | BUB1, BUB1B, BUB3 | CNR1 3404/4885ACHE 4858/4885CNR2 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.